The CD40-CD40 ligand (CD40L) signaling axis plays an important role in immunological pathways. Consequently, this dyad is involved in chronic inflammatory diseases, including atherosclerosis. Inhibition of CD40L in apolipoprotein E (Apoe)-deficient (Apoe / ) mice not only reduced atherosclerosis but also conferred a clinically favorable plaque phenotype that was low in inflammation and high in fibrosis. Blockade of CD40L may not be therapeutically feasible, as long-term inhibition will compromise systemic immune responses. Conceivably, more targeted intervention strategies in CD40 signaling will have less deleterious side effects. We report that deficiency in hematopoietic CD40 reduces atherosclerosis and induces features of plaque stability. To elucidate the role of CD40-tumor necrosis factor receptor-associated factor (TRAF) signaling in atherosclerosis, we examined disease progression in mice deficient in CD40 and its associated signaling intermediates. Absence of CD40-TRAF6 but not CD40-TRAF2/3/5 signaling abolishes atherosclerosis and confers plaque fibrosis in Apoe / mice. Mice with defective CD40-TRAF6 signaling display a reduced blood count of Ly6C high monocytes, an impaired recruitment of Ly6C + monocytes to the arterial wall, and polarization of macrophages toward an antiinflammatory regulatory M2 signature. These data unveil a role for CD40-TRAF6, but not CD40-TRAF2/3/5, interactions in atherosclerosis and establish that targeting specific components of the CD40-CD40L pathway harbors the potential to achieve therapeutic effects in atherosclerosis.
Atherosclerosis is a chronic inflammatory disease of the large arteries that involves multiple immuno logical processes (Hansson, 2005; Weber et al., 2008) . During the progression of atherosclerosis, ongoing activation of the immune system causes continuous recruitment of inflammatory cells into the plaque and degradation of its extracellular matrix. This creates a socalled vulnerable plaque, which is prone to rupture and therefore likely to cause acute complications such as myocardial in farction or stroke (Virmani et al., 2000) . points, as well as in the thoracoabdominal aorta (Fig. 1 a) . This was associated with a less inflammatory and more fi brotic plaque quality, as reflected by the low amount of thin fibrous cap atheromata (Virmani et al., 2000) that developed in absence of CD40 (Fig. S1 a) . The absence of CD40 reduced the lipid core size (ApoE / , 35.4% vs. CD40 / ApoE / , 23.3%; P < 0.05), the number of plaque macrophages, and the content of CD45 + cells and CD3 + T lymphocytes (Figs. 1, b and c) . The number of Foxp3 + regulatory T cells in plaque or adventitia was unaffected (Fig. S1 , b and c). The numbers of cleaved caspase 3 + (apoptotic) cells (Fig. S1 d) , as well as the degree of iron or fibrin deposition in the plaque (not depicted), were unaffected.
Besides the decrease in inflammatory cell content, plaques of CD40 / Apoe / mice had a more fibrotic appearance. The content of -smooth muscle actin (SMA; SMA + cells; Fig. 2 a) and collagen ( Fig. 2 b) was significantly increased. Brightfield polarization microscopy revealed that in the ab sence of CD40, the color distribution of the collagen devi ated toward the red spectrum, indicating larger collagen fibrils (MacKenna and Omens, 1996) . Concordant with these findings, we found an increase in the amount of collagen I and III in the plaque (Fig. 2, d and e) .
Recent studies have identified the involvement of various matrix metalloproteinases in atherosclerotic lesion formation and their contribution to fibrous cap thinning by degrading extracellular matrix (Hansson and Libby, 2006) . Interestingly, MMP2 and MMP9 expression was decreased in the plaques of CD40 / Apoe / mice (Fig. S2, a and b) . To confirm an impairment of proteolytic activity and effects of tissue inhibi tor of metalloproteinase (TIMP) 1, we measured gelatinase activity and TIMP1 messenger RNA (mRNA) levels in macrophages stimulated with the CD40clustering antibody FGK45. We found that gelatinase activity was decreased (Fig. S2 c) , whereas TIMP1 levels were increased in CD40 deficient macrophages (Fig. S2 d) .
Leukocyte CD40 deficiency reduces atherosclerosis and impairs macrophage migration
To unequivocally establish the involvement of leukocyte versus nonleukocyte CD40 in atherosclerosis, we reconsti tuted lethally irradiated Ldlr / mice with CD40 / or WT BM and fed the mice with a highfat diet for 24 wk. Body
The CD40-CD40 ligand (CD40L) dyad, a costimulatory receptorligand pair, plays a crucial role in enhancing immune responses and inflammation and contributes to a plethora of chronic inflammatory diseases, for example, colitis, arthritis, al lergic encephalitis, and multiple sclerosis (Durie et al., 1993; Gerritse et al., 1996; Lutgens et al., 2007; Vowinkel et al., 2007) . Disruption of the CD40L gene in apolipoprotein E (Apoe) / mice abrogated atherosclerosis and caused a plaque phenotype with only few inflammatory cells and a high per centage of extracellular matrix (Lutgens et al., 1999) , which is reminiscent of a clinically favorable stable atherosclerotic plaque in humans (Virmani et al., 2000) . This phenotype was copied when Apoe / mice with initial plaques or established athero mata were treated with a blocking antiCD40L antibody (Mach et al., 1998; Lutgens et al., 2000; Schönbeck et al., 2000) .
In principle, these findings render targeting of CD40L a promising strategy to reduce atherosclerosis and to stabilize atherosclerotic plaques. Unfortunately, clinical trials using an antiCD40L antibody have been omitted as a result of throm boembolic complications, particularly because CD40L is pres ent on platelets and can interact with the integrin  IIb  3 in platelets (Kawai et al., 2000; André et al., 2002) .
Antagonizing CD40, the receptor for CD40L, or its sig naling intermediates would be an alternative approach for treating human atherosclerosis. However, information on the effects of CD40 and CD40associated signal transduction pathways in atherosclerosis is scarce. It has been shown that low-density lipoprotein receptor (Ldlr)-deficient (Ldlr / ) mice lacking the CD40 gene do not develop smaller atheroscle rotic lesions than control Ldlr / mice (Zirlik et al., 2007b) , although a proatherogenic role for endothelial CD40-TNF receptorassociated factor (TRAF) 1, 2, 3, 5, and 6 signaling in atherosclerosis has been claimed (Zirlik et al., 2007a) . Using mice carrying a CD40 transgene with targeted mutations at the CD40TRAF6 recognition site, we found that CD40 TRAF6 signaling is specifically required for arterial neointima formation (Donners et al., 2008) .
In the present study, we tried to elucidate the role of CD40 and its associated signaling intermediates, the TRAFs, in primary atherosclerosis in vivo in detail. We found that CD40 / Apoe / mice had a reduction in atherosclerosis and developed a stable atherosclerotic plaque phenotype. BM transplantation of CD40 / BM into Ldlr / mice revealed that hematopoietic CD40 was responsible for the observed phenotype. Surprisingly, when CD40-TRAF6, but not CD40-TRAF2/3/5, interactions were defective, atheroscle rosis was completely abrogated.
RESULTS

CD40 deficiency reduces atherosclerosis
We generated CD40 / Apoe / mice and analyzed the extent and phenotype of atherosclerosis at 26 wk of age on a normal chow diet. Body weight, as well as cholesterol content or plasma sCD40L levels did not differ between the groups (Table I) .
As in CD40L / Apoe / mice, deficincy of CD40 reduced the atherosclerotic plaque area in the aortic arch and its branch (Fig. 3 a) . Similar to CD40 / Apoe / mice, atherosclerotic plaques of chimeric CD40 / Ldlr / mice contained less Mac3 + macrophages (Fig. 3 b) . In culture, CD40 / macrophages showed an impaired mi gration toward CCL2 (Fig. 3 c) . Moreover, the percentage of CD45 + cells and CD3 + T lymphocytes in the plaque was de creased (Fig. 3 e) . In accordance with this antiinflammatory profile in the plaque, absence of CD40 strongly decreased the expression of IB in FGK45stimulated macrophages (Fig. 3 d) , suggesting that the phenotypic effects are mediated by NFB signaling. Total collagen content (Fig. 3 f) and smooth muscle cell (SMC) content (Fig. 3 f) were increased in the plaque in absence of CD40. These data reveal a crucial role for leukocytedependent CD40 signaling in atherosclerosis.
Deficiency of CD40 polarizes macrophages toward an M2 phenotype Stimulation of CD40 with the clustering antibody FGK45 in BMderived macrophages resulted in a significant induction of the proinflammatory cytokines IL12, iNOS (Fig. 4 a) , and CCL2 (not depicted) and a significant reduction of IL10 (Fig. 4 c) in WT but not in CD40 / macrophages, indicating that absence of CD40 polarizes macrophages toward an M2 phenotype (Martinez et al., 2009) . To further differentiate the M2 subset into woundhealing and regulatory macrophages (Mosser and Edwards, 2008) , realtime PCR analysis for re spective markers was performed in FGK45stimulated BM derived macrophages. We observed that CD40 deficiency significantly reduced the inflammatory M1 markers iNOS and IL12 (Fig. 4 a) , only slightly reduced the expression of the woundhealing macrophage markers YM1 and RELM, and did not affect the expression of arginaseI, IGF1, or DCIR ( Fig. 4 b) , suggesting that CD40 signaling is essential for polarization of macrophages toward the M1 subtype but not toward woundhealing macrophages. Moreover, absence of CD40 did not result in an increase in collagen 1A1 produc tion in these macrophages (Fig. 4 b) . In contrast, deficiency of CD40 strongly induced the regulatory macrophage marker IL10, whereas SPKH1 expression was not affected (Fig. 4 c) , indicating that CD40 deletion shifts the macrophage pheno type to an antiinflammatory regulatory signature.
CD40 deficiency affects T cell and DC phenotype
To elaborate on the immune phenotyping, we performed flow cytometry analysis of blood, spleen, and lymph node cells ( Fig. S3) (Shortman and Liu, 2002) .
CD40-TRAF signaling in atherosclerosis
We next examined which of the CD40associated signal transduction pathways was responsible for the phenotype observed in CD40 / Apoe / mice. CD40 has no intrinsic signaling ability but requires adaptor molecules, TRAFs, to confer signaling. The cytoplasmic tail of CD40 contains three binding domains: a proximal domain that binds TRAF6 and two distal domains that bind TRAF1, TRAF2, TRAF3, and, indirectly, TRAF5 (Zapata, 2003; Lu et al., 2007; Lutgens et al., 2007) . The separate TRAF binding sites are coupled to divergent signaling pathways involving different CD40 downstream modulators and effectors Engel et al., 2009; Lievens et al., 2009) , depending on the target cell types involved. To unravel the contribution of CD40TRAF2/3/5 versus CD40TRAF6 signaling in MH CII + cells to atherosclerosis, we used CD40 / mice express ing a chimeric CD40 transgene with mutations at the TRAF6 and/or TRAF2/3/5 binding site under control of the MH CII promotor (CD40-T2/3/5 / , CD40-T6 / , and CD40-T2/3/5/6 / mice, respectively) or CD40 / mice carrying the transgene without mutations (CD40-Twt mice; Ahonen et al., 2002; Donners et al., 2008) and backcrossed them with Apoe / mice. At 26 wk of age on a normal chow, atheroscle rosis was analyzed in the aortic arch, including its main branch points, and the thoracoabdominal aorta, including the iliac artery bifurcation (unpublished data). Body weight, plasma cholesterol level, and serum sCD40L level did not differ be tween the genotypes (Table I) .
CD40-TRAF2/3/5 signaling does not affect atherosclerosis
The atherosclerotic plaque area, the plaque phenotype (Virmani et al., 2000) , the plaque quality, as evident by the content of the lipid core, Mac3 + cells, CD45 + cells, CD3 + T cells, collagen (I and III), SMCs, cleaved caspase 3, and macrophage polarization did not differ between CD40-T2/3/5 / and CD40-Twt mice, indicating that deficiency in CD40TRAF2/3/5 signaling does not affect atherosclerosis (Figs. 5 and 6). In fact, CD40-T2/3/5 / mice displayed even higher numbers of CD4 + cells (Fig. S4 a) and CD8 + CD44 high CD62L low effector memory T lymphocytes in blood, spleen, and/or lymph nodes than CD40-Twt mice and elevated CD8 + resident DCs (Fig. S3, c and d) , a subtype which is characterized by increased IL12 production (Shortman and Liu, 2002) . This apparently proinflamma tory profile was counterbalanced by elevated numbers of CD4 + CD25 + FoxP3 + regulatory T lymphocytes in blood, spleen, and lymph nodes of CD40-T2/3/5 / mice (Fig. S4 b) . Regulatory T cell function had not changed (Fig. S4 c) , and because of the balanced effector T cell and regulatory T cell ra tio systemic levels of IFN, IL6, TNF, IL12, or IL10 were unaltered (not depicted). Notably, in CD40-T2/3/5 / mice the content of CD4 + CD25 + FoxP3 + regulatory T lym phocytes was also increased in the adventitia underlying the plaques but not in the plaque itself (Fig. S4 d) .
Inhibition of CD40-TRAF6 signaling abolishes atherosclerosis
In a remarkable contrast, deficiency of CD40TRAF6 signal ing almost completely abolished the development of athero sclerosis, as only few intimal xanthomas or fattystreak lesions (classified according to Virmani et al. [2000] ) were detectable in the aortic arch and its branch points (Fig. 5 a) , and no plaques were present in the thoracoabdominal aorta of CD40-T6 / mice (Fig. 5 a) . This reduction of atherosclerosis was even more pronounced than in CD40 / Apoe / mice, likely be cause of the effects of residual CD40TRAF2/3/5 signaling on regulatory T lymphocytes. Concomitantly, macrophage, CD45 + cell, and CD3 + T lymphocyte infiltration, but also collagen (I and III), SMA, and MMP2 and MMP9 content, were substantially reduced in the hardly evolved lesions of CD40-T6 / mice (Fig. 5 , b and c; Fig. 6 ; and Fig. S5 ). The population of peripheral blood Ly6C high monocytes was significantly declined (Fig. 7 a) . Moreover, CD40-T6 / macrophages had an impaired capacity to migrate toward CCL2 (Fig. 7 b) . Intravital microscopy showed that the adhe sion of circulating leukocytes and, in particular, that of Ly6C + monocytes to carotid arteries was significantly impaired in CD40-T6 / mice (Fig. 7, c and d ).
CD40-TRAF6 deficiency polarizes macrophages toward a regulatory M2 phenotype
BMderived macrophages of CD40-T6 / mice stimulated with FGK45 produced less IL12 and iNOS but increased amounts of IL10 (Fig. 8) , indicating that CD40TRAF6 defi ciency skews macrophage polarization toward an antiin flammatory M2 phenotype. Further subtyping of the M2 macrophages into woundhealing and regulatory macro phages (Mosser and Edwards, 2008) showed that CD40-TRAF6 interactions did not affect the woundhealing macrophage markers YM1, RELM, arginase I, IGF1, or DCIR but markedly dampened the M1 polarization response and, rather, induced a regulatory macrophage subtype that produces high amounts of IL10. Importantly, the process of monocyte re cruitment driven by CD40TRAF6 was mediated by IL10, as treatment of CD40T6 / mice with a blocking antibody to IL10 reversed the protective effect on Ly6C + cell numbers and adhesion (Fig. 7 d) . The phenotype that occurs in CD40-T6 / mice is likely associated with an impaired NFB signaling because IB levels in macrophages were markedly decreased (Fig. 8 d) . Consistent with findings in CD40deficient macro phages, CD40-T6 / macrophages displayed a reduced gelati nolytic activity and increased expression of TIMP1 (Fig. S5, c  and d ). Flow cytometry analysis further revealed reduced num bers of CD4 + CD44 high CD62L low promigratory effector mem ory T lymphocytes and plasmacytoid DCs (Figs. S3, c and d) .
Deficiency of CD40-TRAF2/3/5/6 interactions induces plaque fibrosis It is of note that mice with a combined deficiency in CD40 TRAF2/3/5/6 binding were characterized by an intermediate phenotype, further supporting countercuring effects of CD40 TRAF2/3/5 and CD40TRAF6 signaling in atherosclerosis. CD40-T2/3/5/6 / mice showed only a slight reduction in atherosclerosis (Fig. 5 a) but displayed features of atheroscle rotic plaque stability (Fig. 5 a) , with an increased number of fi brocalcific plaques containing smaller lipid cores and reduced CD45 + cell and CD3 + T lymphocyte infiltrations.
Plaques of CD40-T2/3/5/6 / mice exhibited high lev els of collagen (Fig. 6, a-c) and SMA-positive SMCs (3.1 ± 0.7 vs. 5.1 ± 0.9; P < 0.05). Polarized light microscopy on Sirius red-stained sections further showed that the majority of this collagen consisted of large fibrils, as evident by the high percentage of the red fraction (Fig. 8, c and d) . In concor dance with this finding, plaque levels of collagen I were sig nificantly increased, whereas collagen III levels were unaffected (Fig. 6, e and f) . Moreover, plaque MMP2 and MMP9 lev els were significantly reduced in CD40-T2/3/5/6 / mice (Fig. S5, a and b) , indicating a decreased proteolytic activity in these plaques. Accordingly, BMderived macrophages of CD40-T2/3/5/6 / mice treated with CD40clustering anti body FGK45 displayed reduced gelatinolytic activity and ele vated levels of TIMP1 mRNA (Fig. S5, c-e) .
As in CD40-T6 / mice, macrophages of CD40-T2/3/5/6 / mice stimulated with FGK45 exhibited an M2 macrophage profile with decreased IL12 production and in creased production of IL10, whereas ly6C high monocyte num bers and adhesive function were unaffected (Figs. 7 and 8) . CD40-T2/3/5/6 / mice shared increased CD8 + effector memory T lymphocytes with CD40-T2/3/5 / mice and decreased plasmacytoid DC numbers with CD40-T6 / mice (Fig. S3, c and d) . This indicates that some features, namely reduced inflammatory monocyte arrest and macrophage po larization, are exclusive to CD40-T6 / mice and are not compensated for by deficiency of both TRAF binding sites.
DISCUSSION
In this study, we found a clearly divergent action of the two TRAF binding sites of CD40 in atherosclerosis. Deficiency of showed reduced numbers and reduced arterial recruitment of Ly6C high monocytes, the inflammatory monocyte subset which dominates in hyperlipidemia (Swirski et al., 2007; Tacke et al., 2007) , can easily enter the arterial wall, and can differentiate into intimal macrophages. In parallel, CD40-T6 / mice showed a reduction in the classically activated M1 macrophage subset producing iNOS and IL12, which is involved in clearing intracellular parasites or tumors and elicit ing tissue disruption (Gordon, 2003; Mosser and Edwards, 2008) . Macrophages of CD40-T6 / mice were skewed to ward the M2 phenotype and particularly toward the IL10-producing regulatory subtype (Mosser and Edwards, 2008) . Interestingly, the reduced recruitment of Ly6C high mono cytes in the carotid artery of CD40T6 / mice could be reversed by blocking IL10, indicating that there could be a link between the IL10-producing macrophage phenotype and effects on subsequent monocyte recruitment. Surpris ingly, markers of the eponymously termed woundhealing macrophages, which contribute to the healing response after tissue destruction, were unaltered in the absence of CD40-TRAF6 interactions, although high levels of plaque fibrosis were observed in CD40-T2/3/5/6 / mice. However, the rel evance of these data has to be further substantiated and validated CD40-TRAF6 interactions in MHCII + cells nearly abrogated atherosclerosis, an effect more marked than CD40 deletion it self, whereas deficiency of CD40-TRAF2/3/5 interactions did not affect atherosclerosis but, rather, showed a tendency to aggravate atherosclerosis. The CD40-TRAF6 interactions appeared to be specifically required for the proatherogenic ac tivity exerted by cells of the myeloid lineage. Deficiency of CD40-TRAF6 interactions limits the subset of Ly6C high in flammatory monocytes and attenuates their adhesion to and infiltration into the arterial wall, thereby abolishing athero sclerotic plaque formation. The few monocytes that succeed in infiltrating the arterial wall, rather, differentiate into macro phages with an antiinflammatory regulatory M2 signature, thereby preventing plaque inflammation and progression.
In this paper, we provide conclusive evidence for an im portant role of CD40-TRAF6 interactions in the recruitment and fate of monocytes/macrophages. Diversity and plasticity are a hallmark of the monocyte/macrophage lineage, and their phenotype strongly depends on their microenvironment and the inflammatory signals they perceive (Gordon, 2003; Mosser and Edwards, 2008; Auffray et al., 2009) . We found that CD40TRAF6 signaling affects the homeostasis of both monocyte and macrophage polarization. CD40T6 / mice overexpression prevented CD40induced proinflammatory cytokine expression (Urbich et al., 2001) .
A clearer picture of the function of CD40-TRAF2/3/5 interactions has emerged in B cell biology. CD40TRAF2 signaling is crucial for germinal center formation, induces JNK activation, and, in particular, NFB2 activation (Tsukamoto et al., 1999; Au and Yeh, 2007; Vallabhapurapu et al., 2008) . This is in accordance with our findings that IB mRNA expression was not significantly decreased in CD40-T2/3/5 / macrophages. Together with CD40-TRAF5 interactions, which are also required for Ig produc tion, CD40TRAF2 signaling upregulates costimulatory molecules (Au and Yeh, 2007) . In contrast, TRAF3 acts as an inhibitor reducing costimulatory molecule expression and IgM production (Bishop and Xie, 2007) . In cell types and organs other than B cells or lymph nodes, however, most of these functions are irrelevant. Consistent with our data, the overall effect of CD40TRAF2/3/5 signaling with regards to atherogenesis appears to be balanced.
Our findings may harbor new and interesting therapeutic possibilities. The complete inhibition of CD40-CD40L sig naling in atherosclerosis is not therapeutically feasible because longterm treatment will compromise systemic immune re sponses and also entails thromboembolic complications. Therefore, inhibition of the TRAF6 binding site on CD40, using small molecules or an antagonizing CD40 antibody that changes the conformation of the CD40TRAF binding sites, may be a suitable alternative. It is conceivable that the protec tion by CD40TRAF6 blockade is conferred by skewing the immune response to a more antiinflammatory profile, namely through increased production of IL10 and its effects on miti gating the relative propensity, recruitment, and differentiation of proinflammatory monocytes. Not only could inhibition of the CD40TRAF6 binding site reduce atherosclerosis more effectively than a complete inhibition of CD40 or CD40L by avoiding an interference with potentially protective effects by remaining CD40signaling pathways, it may also leave the normal functions of these pathways unaffected, and would therefore be expected to only cause limited side effects. How ever, although our results in the mouse model are promising, caution should be applied when extrapolating these experi mental data to the human situation. The effects of such selec tive targeting strategies will have to be meticulously scrutinized before being translated into a clinical setting.
MATERIALS AND METHODS
Animals. CD40 / , CD40-Twt, CD40-T2/3/5 / , CD40-T6 / , and CD40-T2/3/5/6 / mice (all on a C57Bl6 background; Ahonen et al., 2002) were backcrossed for seven generations to Apoe / mice. Ldlr / mice were purchased from The Jackson Laboratory. All study protocols involving animal experiments were approved by the Animal Care and Use committee of the University of Maastricht and were performed according to official rules formulated in the Dutch law on care and use of experimental animals, which are highly similar to those of the National Institutes of Health.
Primary atherosclerosis. CD40 / Apoe / (n = 16), CD40 +/+ Apoe / (n = 19), CD40-Twt (n = 14), CD40-T2/3/5 / (n = 17), CD40-T6 / (n = 26), and CD40-T2/3/5/6 / (n = 14) mice were fed a normal chow diet through out the experiment. because the functional role of different monocyte and macro phage subsets in atherosclerosis remains to be fully elucidated (Mantovani et al., 2009; Swirski et al., 2009) . For now, our data clearly reveal that a deficiency of CD40-TRAF6 inter actions confers an immuneregulatory phenotype in the monocyte/macrophage lineage, which reduces atherosclerosis and is capable of inducing plaque stability.
In vascular pathobiology, only few data are available on the role CD40-TRAF6 interactions. Recently, CD40-TRAF6 interactions in MHCII + cells have also been impli cated in neointima formation in a mouse ligation model (Donners et al., 2008) . Moreover, it has been observed that stimulation with CD40L induces CD40-TRAF6 interac tions in endothelial cells but that their disruption surpris ingly results in increased expression of CCL2 (Zirlik et al., 2007a) . More evidence has been gathered regarding the role of CD40-TRAF6 interactions in hematopoietic cell types including cells of the myeloid lineage. In B cells, effects of CD40TRAF6 signaling comprise germinal center forma tion, NFB activation, IL6 production, and upregulation of costimulatory molecules (Tsukamoto et al., 1999; Ahonen et al., 2002; Hostager, 2007) . In monocytes/macrophages, CD40-TRAF6 interactions induce NFB and ERK activation, as well as the production of TNF and IL6 (Mukundan et al., 2005) . In DCs, CD40TRAF6 signaling is required for MHCII surface expression and IL6 and IL 12 production (Kobayashi et al., 2003) . Differences in the effector functions of CD40TRAF6 signaling between the various cell types may be a result of contextspecific embed ding of downstream pathways.
Our data further show that CD40-TRAF2/3/5 interac tions on MHCII + cells appear to be required for maintaining T lymphocyte homeostasis in atherosclerosis. Absence of CD40-TRAF2/3/5 interactions increased the numbers of CD4 + T cells and promigratory CD8 + CD44 high CD62L low ef fector memory T lymphocytes, which by itself would likely be sufficient to aggravate atherosclerosis. However, the increase in T cells was compensated by an increase in CD4 + CD25 + FoxP3 + regulatory T lymphocytes, both sys temically and in the vasculature. This expansion of regulatory T cells as an atheroprotective T cell subtype (AitOufella et al., 2006) may protect CD40-T2/3/5 / mice against the T cell-induced exacerbation of atherosclerosis.
Data on the role of CD40T2/3/5 signaling in vascular biology are scarce and not uniform, as the induction of CD40TRAF2/3/5 signaling yields different outcomes de pending on the cell types and pathologies involved. Consis tent with the present study, we did not find an effect on neointima formation after carotid artery ligation in CD40 T2/3/5 / mice (Donners et al., 2008) . However, TRAF2 / and TRAF5 / endothelial cells failed to produce IL6 upon stimulation with CD40L, whereas CCL2 induction was unaffected (Zirlik et al., 2007a) . In areas with high shear stress, TRAF3 expression in endothelial cells covering human atherosclerotic plaques is upregulated and may act as a feedback mechanism limiting endothelial activation, as its BM transplantation. Ldlr / mice (n = 44) were maintained in filtertop cages and given water containing 60,000 U/liter polymyxin B sulfate (Invit rogen) and 100 mg/liter neomycin (Invitrogen) from 1 wk before BM trans plantation until 4 wk thereafter. Mice were lethally irradiated (10 Gy, 0.5 Gy/min; MU 15F/225 kV; Philips) and i.v. injected with 10 7 BM cells from CD40 / mice or CD40 +/+ mice. 4 wk after transplantation, mice were fed a 1.25% cholesterol diet for 24 wk.
Atherosclerosis experiments. Mice were sacrificed and the arterial tree was perfused. The aortic arch and its main branch points were excised, fixed over night, and embedded in paraffin. The rest of the arterial tree was fixed, opened, pinned, and stained with OilredO for en face analysis. Longitudinal sections of the aortic arch were analyzed for plaque extent and phenotype as previously described (Virmani et al., 2000; Lutgens et al., 2006) . For phenotypic parame ters, immunohistochemistry was performed for CD3 (Dako), CD45 (BD), mac3 (BD), FVIII (Dako), SMA (SigmaAldrich), caspase 3 (Cell Signaling Technology), FoxP3 (eBioscience), collagen I (Abcam), collagen III (Abcam), MMP2 (Cell Signaling Technology), MMP9 (Santa Cruz Biotechnology, Inc.). In addition, Perl's iron staining and Sirius red staining were as previously described (Lutgens et al., 2006) . Morphometric analyses were performed using a Quantimet (Leica) with Qwin3 software (Leica). Plasma cholesterol levels were measured enzymatically (Roche), organs were analyzed by hematoxylin and eosin staining, and no abnormalities were observed. Serum sCD40L levels were measured by ELISA (eBioscience).
In vitro macrophage culture. BM cells were isolated from n = 6 mice/ group and cultured in RPMI supplemented with L929 conditioned medium to generate BMderived macrophages as previously described (Kanters et al., 2003) . Cells were pretreated with 100 U IFN for 24 h to induce MHCII expression and then treated for 3 h with 100 ng/ml FGK45, a CD40stimulat ing antibody. Cytokine levels in the medium were measured by FACS using a cytometric bead assay (BD), and quantitative gene expression of cytokines, M1, and M2 macrophage markers were analyzed as previously described .
Macrophage migration assay. Macrophage migration was assessed using 24well Transwell migration chambers (Costar; Corning) with a pore size of 6 µm. BMderived macrophages (0.5 × 10 6 ) of the respective genotypes, sus pended in serumfree medium, were added to each chamber. Complete me dium, including 100 ng/ml CCL2 (R&D Systems), was added to the lower chambers and migration was performed at 37°C for 4 h. Nonmigrated cells were removed from the membranes, and migrated cells within the membrane were fixed with methanol and stained with toluidine blue. Membranes were cut out of inserts and mounted onto slides in immersion oil. The number of migrated cells was counted on five randomly chosen fields of each membrane.
Gelatinase assay. Gelatinase activity in the supernatant of FGK45treated macrophages was determined using the EnzChek gelatinase/collagenase assay kit (Invitrogen). Substrate hydrolysis was analyzed after 24 h at room tempera ture and fluorescence was detected using a fluorescence microplate reader.
Intravital microscopy. Leukocyte endothelial interactions were analyzed by intravital microscopy of the left carotid artery (n = 8 mice/group; Koenen et al., 2009) . 6 h after i.p. injection of 1.0 µg of mouse TNF (PeproTech), mice were anaesthetized with ketamine/xylazine and the left carotid artery was exposed. Circulating leukocytes were labeled by i.v. injection of rhoda mine 6G. Ly6C + inflammatory monocytes were labeled with fluorescent latex beads as previously described (Soehnlein et al., 2008) . The antibody to IL10 (clone JES5.2A) was injected twice i.p. (500 µg/mouse), 24 and 2 h before intravital microscopy. Recordings were made using a microscope (BX51; Olympus) equipped with a salineimmersion 20× objective.
Statistics. Data are presented as mean ± SEM. Data were analyzed by a nonparametric MannWhitney U test or Welchcorrected t test, as appropri ate, using Prism 4 software (GraphPad Software, Inc.). Pvalues <0.05 were considered significant. Online supplemental material. Fig. S1 shows additional phenotypic fea tures of the atherosclerotic plaques of CD40 / Apoe / mice (classification of Virmani et al. [2000] , Caspase 3 and FoxP3 levels). Fig. S2 shows MMP2 and MMP9 levels in plaques of CD40 / Apoe / mice, as well as gelatinase activity and TIMP1 levels in their BMderived macrophages. Fig. S3 shows the extended immune phenotyping of splenocytes in all the experimental groups. Fig. S4 shows the balanced effector T cell phenotype in absence of CD40TRAF2/3/5 interactions. Fig. S5 shows MMP2 and MMP9 levels in plaques of the CD40-TRAF mice, as well as gelatinase activity and TIMP1 levels in their BMderived macrophages. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20091293/DC1.
